These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8672726)

  • 1. Repair of the in vitro HIV-1-induced immunosuppression and blockade of the generation of functional suppressive CD8 cells by anti-alpha interferon and anti-Tat antibodies.
    Lachgar A; Bernard J; Bizzini B; Astgen A; Le Coq H; Fouchard M; Chams V; Feldman M; Burny A; Zagury JF
    Biomed Pharmacother; 1996; 50(1):13-8. PubMed ID: 8672726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.
    Zagury D; Lachgar A; Chams V; Fall LS; Bernard J; Zagury JF; Bizzini B; Gringeri A; Santagostino E; Rappaport J; Feldman M; Burny A; Gallo RC
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3851-6. PubMed ID: 9520456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.
    Gallo RC; Burny A; Zagury D
    DNA Cell Biol; 2002 Sep; 21(9):611-8. PubMed ID: 12396603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of alpha interferon (alpha IFN) to HIV-induced immunosuppression.
    Lachgar A; Bizzini B
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):431-7. PubMed ID: 7580838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies.
    Mhashilkar AM; LaVecchio J; Eberhardt B; Porter-Brooks J; Boisot S; Dove JH; Pumphrey C; Li X; Weissmahr RN; Ring DB; Ramstedt U; Marasco WA
    Hum Gene Ther; 1999 Jun; 10(9):1453-67. PubMed ID: 10395371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine.
    Gallo RC
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8324-6. PubMed ID: 10411869
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.
    Zagury JF; Sill A; Blattner W; Lachgar A; Le Buanec H; Richardson M; Rappaport J; Hendel H; Bizzini B; Gringeri A; Carcagno M; Criscuolo M; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):282-92. PubMed ID: 10195253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.
    Agwale SM; Shata MT; Reitz MS; Kalyanaraman VS; Gallo RC; Popovic M; Hone DM
    Proc Natl Acad Sci U S A; 2002 Jul; 99(15):10037-41. PubMed ID: 12096189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of alpha-interferon in HIV-1 induced immunosuppression. A potential target for AIDS prophylaxis and treatment.
    Lachgar A; Bizzini B
    Biomed Pharmacother; 1994; 48(2):73-7. PubMed ID: 7919108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat.
    Poznansky MC; Foxall R; Mhashilkar A; Coker R; Jones S; Ramstedt U; Marasco W
    Hum Gene Ther; 1998 Mar; 9(4):487-96. PubMed ID: 9525310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.
    Gringeri A; Santagostino E; Muça-Perja M; Mannucci PM; Zagury JF; Bizzini B; Lachgar A; Carcagno M; Rappaport J; Criscuolo M; Blattner W; Burny A; Gallo RC; Zagury D
    J Hum Virol; 1998; 1(4):293-8. PubMed ID: 10195254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.
    Viscidi RP; Mayur K; Lederman HM; Frankel AD
    Science; 1989 Dec; 246(4937):1606-8. PubMed ID: 2556795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental gene therapy: the transfer of Tat-inducible interferon genes protects human cells against HIV-1 challenge in vitro and in vivo in severe combined immunodeficient mice.
    Sanhadji K; Leissner P; Firouzi R; Pelloquin F; Kehrli L; Marigliano M; Calenda V; Ottmann M; Tardy JC; Mehtali M; Touraine JL
    AIDS; 1997 Jul; 11(8):977-86. PubMed ID: 9223731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients.
    Re MC; Furlini G; Vignoli M; Ramazzotti E; Zauli G; La Placa M
    Clin Diagn Lab Immunol; 1996 Mar; 3(2):230-2. PubMed ID: 8991642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
    Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
    Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-7 receptor expression on CD8 T-cells is downregulated by the HIV Tat protein.
    Faller EM; McVey MJ; Kakal JA; MacPherson PA
    J Acquir Immune Defic Syndr; 2006 Nov; 43(3):257-69. PubMed ID: 16967044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV type 1 envelope glycoprotein 120 carboxy-terminal peptide-induced human T cell lines selectively suppress heterogeneous proliferative T cell responses to soluble antigens.
    Wilson SE; Habeshaw JA; Addawe MA; Hounsell EF; Oxford JS
    AIDS Res Hum Retroviruses; 1997 Oct; 13(15):1313-24. PubMed ID: 9339848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses.
    Richardson MW; Mirchandani J; Silvera P; Régulier EG; Capini C; Bojczuk PM; Hu J; Gracely EJ; Boyer JD; Khalili K; Zagury JF; Lewis MG; Rappaport J
    DNA Cell Biol; 2002 Sep; 21(9):637-51. PubMed ID: 12396606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.